Skip to content
MarketScale
‹ Back to IndustriesSciences

Trends in Pet and Animal Wellbeing

Nutrition, supplements, and wellness are the foundation for a healthy human life. And that trend is now leaking into our pets and animal health. According to a recent Pet Age report, “a pet’s health and wellness is a three-dimensional sphere that includes several interdependent parts including a high-quality diet, regular exercise, routine veterinary care,…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Michelle Dawn Mooney · Animal SupplementsAnimal WellbeingMicrobiomePet Health
Share

Key takeaways

01

Nutrition, supplements, and wellness are the foundation for a healthy human life.

02

And that trend is now leaking into our pets and animal health.

03

According to a recent Pet Age report, “a pet’s health and wellness is a three-dimensional sphere that includes several interdependent parts including a high-quality diet, regular exercise, routine veterinary care,…

Nutrition, supplements, and wellness are the foundation for a healthy human life. And that trend is now leaking into our pets and animal health. According to a recent Pet Age report, “a pet’s health and wellness is a three-dimensional sphere that includes several interdependent parts including a high-quality diet, regular exercise, routine veterinary care, a loving home, and supplements to support health.”

Caitlin Donohue, Director of Business Development Microbiome Solutions, Pet & Animal Wellbeing, ADM Nutrition, pointed out, “it’s a lot cheaper to prevent problems than to treat them.” She and her colleague, Bill Bae, Business Development Director, Market Ready Solutions – NA&LATAM, Pet and Animal Wellbeing, ADM Nutrition, sat down with host Michelle Dawn Mooney to discuss supplement care for pets. Bae continued, “having those supplements… is really beneficial for your pets in general.”

Consumers should expect to see more supplements for their pets’ microbiome. The term microbiome describes a community of different organisms. The gut microbiome and oral microbiome are the most studied. Each community is a competition between desirable bacteria and undesirable bacteria. A healthy microbiome is usually reflective of overall good health.

Supporting supplemental ingredients include pre-, pro-, and post-biotics. “The prebiotic is the food that the probiotics need,” explained Bae. A newer term, postbioitics, are organisms that are no longer living. “Each provides a health benefit. Post is derived from the probiotic, and ultimately promoting a more diverse, beneficial microbiome for the host, be it a dog, cat, or human,” explained Donohue.

Enzyme-focused supplements help facilitate proper digestion. “Enzymes are another way to support a breakdown of other various diets for cats and dogs,” said Donohue. These can help balance pet diets and support overall well-being. “Systemic enzymes support bodily functions within the tissues, organs, blood flow, things like that,” said Donohue.

Bae warns that consumers should do their research when buying pet supplements. Carefully look at what is going into your pet’s gut flora. Bae says there are “macro terms that cover a lot of things.” Delivering supplements is possible in various forms, from single-serve packs, chews, broths, pastes, or gels.

About the author

MD

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MD
Michelle Dawn Mooney

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512